Allelotyping, microsatellite instability, and braf mutation analyses in common and atypical melanocytic nevi and primary cutaneous melanomas

American Journal of Dermatopathology

Volumn 31, Issue 4, 2009, Pages 354-363

  Uribe, Pablo ^a   Wistuba, Ignacio I ^a,b   Gonzalez, Sergio ^a,c  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

BRAF; LOH; Melanoma; MSI; Nevi

Indexed keywords

B RAF KINASE;

ALLELE; ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DYSPLASTIC NEVUS; FEMALE; GENE DELETION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOCYTIC NEVUS; MELANOGENESIS; MELANOMA; MICRODISSECTION; MICROSATELLITE INSTABILITY; MICROSATELLITE MARKER; MISMATCH REPAIR; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL;

ALLELES; DNA MISMATCH REPAIR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LOSS OF HETEROZYGOSITY; MICRODISSECTION; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; NEVUS, PIGMENTED; POINT MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS;

EID: 67650314462     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/DAD.0b013e318185d205     Document Type: Article

References (66)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Clark WH Jr, Elder DE, Guerry DT, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984;15:1147-1165.
3. Duray PH, Ernstoff MS. Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Clinicopathologic experience in a 100-bed hospital. Arch Dermatol. 1987;123:80-84.
4. Rhodes AR, Harrist TJ, Day CL, et al. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol. 1983;9:563-574.
5. Sober AJ, Burstein JM. Precursors to skin cancer. Cancer. 1995;75: 645-650.
6. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med. 2002;347:1593-1603.
7. Pollock PM, Trent JM. The genetics of cutaneous melanoma. Clin Lab Med. 2000;20:667-690.
8. Omholt K, Karsberg S, Platz A, et al. Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res. 2002;8:3468-3474.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
10. Knudson AG. Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol. 1996;122:135-140.
11. Healy E, Belgaid CE, Takata M, et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res. 1996;56: 589-593.
12. Peris K, Keller G, Chimenti S, et al. Microsatellite instability and loss of heterozygosity in melanoma. J Invest Dermatol. 1995;105:625-628.
13. Fujiwara Y, Hoon DS. Microsatellite analysis of melanoma lesions using (CA)13 oligonucleotides as an internal probe. Int J Oncol. 2000;17: 783-787.
14. Robertson GP, Goldberg EK, Lugo TG, et al. Functional localization of a melanoma tumor suppressor gene to a small (< or = 2 Mb) region on 11q23. Oncogene. 1999;18:3173-3180.
15. Tomlinson IP, Beck NE, Bodmer WF. Allele loss on chromosome 11q and microsatellite instability in malignant melanoma. Eur J Cancer. 1996; 32A:1797-1802.
16. Stark M, Hayward N. Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 2007;67:2632-2642.
17. Lee JY, Dong SM, Shin MS, et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun. 1997;237:667-672.
18. Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol. 1998;29:127-130.
19. Maitra A, Gazdar AF, Moore TO, et al. Loss of heterozygosity analysis of cutaneous melanoma and benign melanocytic nevi: laser capture microdissection demonstrates clonal genetic changes in acquired nevocellular nevi. Hum Pathol. 2002;33:191-197.
20. Tran TP, Titus-Ernstoff L, Perry AE, et al. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States). Cancer Causes Control. 2002;13: 675-682.
21. Hussein MR, Sun M, Roggero E, et al. Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas. Mol Carcinog. 2002;34:35-44.
22. Birindelli S, Tragni G, Bartoli C, et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer. 2000;86: 255-261.
23. Hussein MR, Sun M, Tuthill RJ, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol. 2001;28:343-350.
24. Indsto JO, Cachia AR, Kefford RF, et al. X inactivation, DNA deletion, and microsatellite instability in common acquired melanocytic nevi. Clin Cancer Res. 2001;7:4054-4059.
25. Palmieri G, Ascierto PA, Cossu A, et al. Assessment of genetic instability in melanocytic skin lesions through microsatellite analysis of benign naevi, dysplastic naevi, and primary melanomas and their metastases. Melanoma Res. 2003;13:167-170.
26. Richetta A, Ottini L, Falchetti M, et al. Instability at sequence repeats in melanocytic tumours. Melanoma Res. 2001;11:283-289.
27. Rubben A, Bogdan I, Grussendorf-Conen EI, et al. Loss of heterozygosity and microsatellite instability in acquired melanocytic nevi: towards a molecular definition of the dysplastic nevus. Recent Results Cancer Res. 2002;160:100-110.
28. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53-62.
29. Uribe P, Wistuba II, Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003;25:365-370.
30. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33:19-20.
31. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418:934.
32. Wistuba II, Behrens C, Milchgrub S, et al. Comparison of molecular changes in lung cancers in HIV-positive and HIV-indeterminate subjects. JAMA. 1998;279:1554-1559.
33. Wistuba II, Berry J, Behrens C, et al. Molecular changes in the bronchial epithelium of patients with small cell lung cancer. Clin Cancer Res. 2000; 6:2604-2610.
34. Healy E, Rehman I, Angus B, et al. Loss of heterozygosity in sporadic primary cutaneous melanoma. Genes Chromosomes Cancer. 1995;12: 152-156.
35. Healy E, Belgaid C, Takata M, et al. Prognostic significance of allelic losses in primary melanoma. Oncogene. 1998;16:2213-2218.
36. Stanbridge EJ. Identifying tumor suppressor genes in human colorectal cancer. Science. 1990;247:12-13.
37. O'Connell P, Pekkel V, Fuqua SA, et al. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst. 1998;90:697-703.
38. Murphy GF, Mihm MC Jr. Recognition and evaluation of cytological dysplasia in acquired melanocytic nevi. Hum Pathol. 1999;30:506-512.
39. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353:2135-2147.
40. Uribe P, Andrade L, Gonzalez S. Lack of association between BRAF mutation and MAPK ERK activation in melanocytic nevi. J Invest Dermatol. 2006;126:161-166.
41. Wistuba II, Bryant D, Behrens C, et al. Comparison of features of human lung cancer cell lines and their corresponding tumors. Clin Cancer Res. 1999;5:991-1000.
42. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525-532.
43. Wistuba II, Behrens C, Virmani AK, et al. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res. 2000;60: 1949-1960.
44. Wistuba II, Montellano FD, Milchgrub S, et al. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 1997;57:3154-3158.
45. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res. 2000;60:6116-6133.
46. Ohta M, Berd D, Shimizu M, et al. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer. 1996;65:762-767.
47. Pollock PM, Welch J, Hayward NK. Evidence for three tumor suppressor loci on chromosome 9p involved in melanoma development. Cancer Res. 2001;61:1154-1161.
48. Faulkner SW, Leigh DA, Oosterhuis JW, et al. Allelic losses in carcinoma in situ and testicular germ cell tumours of adolescents and adults: evidence suggestive of the linear progression model. Br J Cancer. 2000;83: 729-736.
49. Mosse YP, Greshock J, Margolin A, et al. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma. Genes Chromosomes Cancer. 2005;43:390-403.
50. Mendes-da-Silva P, Moreira A, Duro-da-Costa J, et al. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol Pathol. 2000;53:184-187.
51. Fujiwara Y, Chi DD, Wang H, et al. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients. Cancer Res. 1999;59:1567-1571.
52. Millikin D, Meese E, Vogelstein B, et al. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res. 1991;51:5449-5453.
53. Miele ME, Jewett MD, Goldberg SF, et al. A human melanoma metastasis-suppressor locus maps to 6q16.3-q23. Int J Cancer. 2000;86:524-528.
54. Barghorn A, Speel EJ, Farspour B, et al. Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors. Am J Pathol. 2001;158:1903-1911.
55. Smith LT, Lin M, Brena RM, et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA. 2006;103:982-987.
56. Liu Y, Emilion G, Mungall AJ, et al. Physical and transcript map of the region between D6S264 and D6S149 on chromosome 6q27, the minimal region of allele loss in sporadic epithelial ovarian cancer. Oncogene. 2002; 21:387-399.
57. Shridhar V, Staub J, Huntley B, et al. A novel region of deletion on chromosome 6q23.3 spanning less than 500 Kb in high grade invasive epithelial ovarian cancer. Oncogene. 1999;18:3913-3918.
58. Abe T, Makino N, Furukawa T, et al. Identification of three commonly deleted regions on chromosome arm 6q in human pancreatic cancer. Genes Chromosomes Cancer. 1999;25:60-64.
59. Deng CX, Brodie SG. Roles of BRCA1 and its interacting proteins. Bioessays. 2000;22:728-737.
60. Berney CR, Fisher RJ, Yang J, et al. Genomic alterations (LOH, MI) on chromosome 17q21-23 and prognosis of sporadic colorectal cancer. Int J Cancer. 2000;89:1-7.
61. Dai Q, Deubler DA, Maxwell TM, et al. A common deletion at chromosomal region 17q21 in sporadic prostate tumors distal to BRCA1. Genomics. 2001;71:324-329.
62. De Marchis L, Cropp C, Sheng ZM, et al. Candidate target genes for loss of heterozygosity on human chromosome 17q21. Br J Cancer. 2004;90: 2384-2389.
63. Slattery ML, Potter JD, Curtin K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001;61:126-130.
64. Koinuma K, Shitoh K, Miyakura Y, et al. Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer. 2004;108:237-242.
65. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res. 2003;63:5209-5212.
66. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24:4340-4346.